Bravo María José, Burgos-Molina Antonio Manuel, García-Aranda Marilina, Redondo Maximino, Téllez Teresa
Surgery, Biochemistry and Immunology Department, School of Medicine, University of Malaga, 29010 Malaga, Spain.
Research Network on Chronic Diseases, Primary Care and Health Promotion (RICAPPS), Carlos III Health Institute (Instituto de Salud Carlos III). Av. De Monforte de Lemos, 5, 28029 Madrid, Spain.
Cancers (Basel). 2023 Nov 21;15(23):5499. doi: 10.3390/cancers15235499.
Cancer is one of the world's most significant health problems today. Currently, breast cancer has globally surpassed lung cancer as the most commonly diagnosed cancer in women. In 2020, an estimated 2,261,419 new cases were diagnosed in women worldwide. Therefore, there is a need to understand the processes that can help us better treat this disease. In recent years, research in the fight against cancer has often been based on two treatment modalities. One of them is the use of protein kinase inhibitors, which have been instrumental in the development of new therapeutic strategies. Another crucial route is the use of immunotherapy, which has been touted as a great promise for cancer treatment. Protein kinase alterations can interfere with the effectiveness of other treatments, such as immunotherapy. In this review, we will analyze the role played by protein kinase alterations in breast cancer and their possible impact on the effectiveness of the response to immunotherapy treatments.
癌症是当今世界最严重的健康问题之一。目前，乳腺癌在全球范围内已超过肺癌，成为女性中最常被诊断出的癌症。2020年，全球估计有2261419名女性被诊断出患有新病例。因此，有必要了解那些能帮助我们更好治疗这种疾病的过程。近年来，抗癌研究通常基于两种治疗方式。其中之一是使用蛋白激酶抑制剂，其在新治疗策略的开发中发挥了重要作用。另一条关键途径是使用免疫疗法，它被誉为癌症治疗的巨大希望。蛋白激酶改变会干扰其他治疗方法的有效性，如免疫疗法。在本综述中，我们将分析蛋白激酶改变在乳腺癌中所起的作用及其对免疫治疗反应有效性的可能影响。
Zotero 插件
